Can Recurrent Ovarian Cancer Be Operated Again?

If ovarian cancer has come back, another operation may be considered—but only for carefully selected patients. The operation is called secondary cytoreductive surgery (secondary CRS), also known as repeat debulking surgery. Its aim is to remove all visible recurrent cancer safely. It is not automatically the right treatment for every recurrence, and the decision should be made by a gynaecological-oncology team after reviewing the timing and pattern of recurrence, previous treatment, scans, overall health and the likelihood of complete tumour removal.

In plain words, a second operation is most often considered when the cancer has come back for the first time, more than about 6 months after the last platinum chemotherapy, the patient is fit for major surgery, there is little fluid in the abdomen, and the scans suggest that all the cancer can be removed. If these conditions are not met, medicines are usually the main treatment, and that is not giving up. Families searching in Hindi often ask andashay ka cancer (अंडाशय का कैंसर) wapas aa gaya, kya dobara operation ho sakta hai?

This page explains the questions patients and families often ask: “Can recurrent ovarian cancer be operated again?”, “Why might the spleen or bowel need to be removed?”, and “Would chemotherapy be better than surgery in my case?” Individual advice requires review of the complete medical record.

What does it mean when ovarian cancer has come back?

Recurrent ovarian cancer means the cancer has returned after initial treatment. Recurrence can occur in one area, in several abdominal or pelvic sites, in lymph nodes, or more widely. The term also includes recurrence of fallopian-tube and primary peritoneal cancers that are treated along similar pathways.

A recurrence does not have one standard treatment. Doctors consider how long it has been since platinum chemotherapy, how the cancer responded previously, the number and location of new deposits, symptoms, tumour biology, genetic or molecular test results, and the patient’s general fitness. Treatment may involve chemotherapy, targeted or maintenance treatment, surgery, symptom-directed care, or a planned combination.

Can recurrent ovarian cancer be operated again?

Yes, some patients can have surgery again. The important question is whether secondary CRS is likely to remove all visible disease with an acceptable level of risk. Surgery that knowingly leaves substantial visible cancer is less likely to provide the intended benefit.

Current European guidance recommends that patients with a first relapse more than six months after completing first-line platinum chemotherapy should be assessed for secondary CRS at a centre experienced in ovarian-cancer surgery. Assessment does not mean that surgery will necessarily be recommended.

How will the team decide whether I can have another operation?

There is no single scan finding or blood-test result that decides suitability. Features that may support a surgical assessment include:

a first recurrence after a meaningful treatment-free interval
disease that appears completely removable on specialist imaging review
good physical fitness for another major operation
little or no significant abdominal fluid (ascites)
complete removal of visible cancer at the first operation, or an otherwise favourable earlier disease pattern
availability of a surgical team able to manage bowel, upper-abdominal, splenic or urinary-tract involvement when required

These are assessment factors rather than guarantees. Age alone should not make the decision, and a normal CA-125 does not by itself rule recurrence in or out. The team should consider the full clinical picture and the patient’s priorities.

Does another operation help everyone?

Large randomised trials have not produced identical results. In the DESKTOP III trial, carefully selected patients with platinum-sensitive first relapse had longer overall survival when surgery followed by chemotherapy was compared with chemotherapy alone, and complete resection was achieved in about three-quarters of those who underwent surgery. On average (median), women in the surgery group lived about 54 months compared with 46 months with chemotherapy alone, and those whose cancer was completely removed did best. The GOG-0213 trial did not show an overall-survival advantage from adding surgery to chemotherapy in its study population; in that trial complete removal was achieved in about two-thirds of operated patients, and most patients also received bevacizumab.

These results should not be reduced to “surgery always works” or “surgery never works.” The trials used different selection approaches and systemic-treatment patterns. They reinforce two practical points: patient selection matters, and the realistic chance of complete visible tumour removal matters. A recommendation should explain why the team believes surgery is or is not appropriate for the individual patient.

What might be removed during the operation?

Secondary CRS is a treatment strategy rather than one fixed operation. The procedures required depend on where recurrent disease is located. Surgery may involve removal of isolated tumour deposits, adhesiolysis to separate tissues affected by previous operations, lymph-node excision, peritoneal stripping, bowel resection, diaphragm or liver-surface procedures, or removal of the spleen.

This list does not mean every patient needs a multi-organ operation. Before consent, the surgeon should explain the expected procedure, additional steps that might become necessary, the possibility of a stoma, the chance that complete removal may not be feasible, and when the operation might be stopped for safety.

Why might my spleen need to be removed?

Splenectomy means surgical removal of the spleen. In recurrent ovarian cancer, it may be considered when a deposit involves the spleen or the splenic hilum and removal is necessary to achieve complete CRS. An isolated splenic recurrence is uncommon; more often, the decision is part of a wider assessment of abdominal disease.

The spleen helps protect against certain infections. If splenectomy is planned, the team should discuss vaccination against infections associated with loss of splenic function, the timing of those vaccines, fever precautions and whether any longer-term preventive treatment is needed. The exact vaccination plan should follow the patient’s medical history and current local guidance.

How difficult is repeat surgery and recovery?

The risk depends on the extent of surgery, previous operations, adhesions, organs involved, nutrition and general health. Possible complications include bleeding, infection, blood clots, chest complications, injury to nearby organs, bowel or urinary leakage, delayed return of bowel function, wound problems, a temporary or permanent stoma, and the need for intensive monitoring.

Splenectomy adds specific considerations, including bleeding around the splenic vessels, nearby pancreatic or stomach injury, and a lifelong increase in susceptibility to some serious infections. Ask the team how these risks apply to the proposed operation rather than relying on a general complication list.

Will I still need chemotherapy after surgery?

Secondary CRS is usually considered as one part of a broader treatment plan. Many patients receive systemic treatment after surgery. The choice may depend on previous medicines, the interval since platinum treatment, pathology, response, BRCA or homologous-recombination findings, previous maintenance therapy, side effects and other health conditions.

For patients who are not suitable for surgery, systemic treatment may still control disease and symptoms. A decision against surgery does not mean there are no treatment options.

Is HIPEC routinely used for recurrent ovarian cancer?

No. HIPEC is not a routine addition to every secondary CRS operation for recurrent ovarian cancer. Evidence, eligibility and practice vary by clinical situation. It should be discussed separately from the decision about whether recurrent disease can be completely removed. If HIPEC is proposed, ask what evidence supports its use in your exact setting, what medicine and protocol would be used, and how it changes risk and recovery. Read the separate guide to HIPEC surgery. When HIPEC is suitable, Dr. Nishtha Tripathi Patel performs it at Sterling Hospitals and KD Hospital, Ahmedabad.

Can the operation be done through small cuts?

Some isolated recurrences may be suitable for robotic or laparoscopic surgery, but extensive or multi-site disease commonly requires open surgery. The safest route depends on the location of recurrence, previous operations, adhesions and the procedures needed. A smaller incision should not take priority over complete and safe cancer surgery.

Ask why a particular surgical route is recommended and whether the plan could change after the abdomen is assessed. The main goal is appropriate cancer treatment, not use of a particular technology.

What should we expect when I come home?

Recovery varies from a focused procedure to a major multi-organ operation. Planning may include pain control, blood-clot prevention, breathing exercises, early mobilisation, nutrition support, bowel and bladder care, management of a stoma if one is created, and coordination of further cancer treatment.

Before discharge, patients should receive clear instructions about medicines, wound care, eating and drinking, activity, follow-up and whom to contact. Seek urgent medical advice for fever, difficulty breathing, persistent vomiting, worsening abdominal pain, heavy bleeding, wound discharge, inability to drink, or new confusion. After splenectomy, fever requires prompt medical assessment because infection can become serious quickly.

What if another operation is not suitable for me?

A decision against surgery does not mean treatment has stopped. Chemotherapy, targeted or maintenance medicines, focused procedures for symptoms and supportive care may still be appropriate. The team should explain the goal of each option and why it may suit the pattern of recurrence better than an operation.

If the reason is unclear, ask whether the concern is that all visible cancer cannot be removed, that the operation would be too risky, or that another treatment is more likely to help. A specialist second opinion may be useful when different teams recommend different approaches.

How can family members help after repeat surgery?

Help may be needed with medicines, meals, walking, wound or stoma care, transport and follow-up appointments. The level and duration vary greatly with the operation. Before discharge, family members should know whom to contact and which symptoms need urgent assessment.

Questions to ask before deciding about another operation

Where has the cancer returned, and is it the first recurrence?
What is the interval since my last platinum chemotherapy?
Does the team believe all visible disease can be removed? Why?
What organs might need treatment or removal?
Could I need bowel surgery, a stoma or splenectomy?
What would make the surgeon stop or change the operation?
What are the important risks in my individual case?
What treatment would follow surgery?
What are the alternatives if I do not have surgery?
Has my case been discussed by a multidisciplinary team?

What to bring for a secondary CRS opinion

Bring the original pathology report, details of the first operation, chemotherapy and maintenance-treatment records, recent CT/MRI/PET reports and image files, CA-125 trends, molecular or genetic test results, discharge summaries, current medicines and information about other health conditions. The operative note from the first surgery can be especially useful. A simple checklist is in our guide to preparing for a specialist appointment.

A gynaecological-cancer second opinion can help when the chance of complete removal is uncertain, the proposed surgery includes several organs, or different teams have recommended different approaches. You can also review the main ovarian cancer guide, the explanation of cytoreductive surgery (CRS), and Dr Nishtha Tripathi Patel’s academic work on secondary CRS.

Frequently asked questions

Does ovarian cancer coming back mean it cannot be treated?

No. Recurrent ovarian cancer can often be treated, although the aim and choice of treatment vary. Options may include systemic treatment, surgery for selected patients, symptom-directed procedures and supportive care.

What are the signs that ovarian cancer has come back?

Some women notice bloating, a swollen tummy, pain in the lower abdomen or pelvis (pet ke neeche dard), feeling full quickly, a change in bowel habit or tiredness. Often there are no symptoms and the return is first suggested by a rising CA-125 or a follow-up scan. These symptoms have many non-cancer causes, but do not wait for the next routine visit if they are new and persistent: tell the treating team so they can arrange the right tests.

What if the cancer came back within 6 months of chemotherapy?

Doctors call this platinum-resistant recurrence. A second operation is less often helpful in this situation, and the European guidance on surgical assessment applies to relapse more than six months after platinum chemotherapy. Treatment usually relies on other medicines, clinical trials where available, and good symptom control. The team should explain the aim of each option in your situation.

Does a rising CA-125 mean I need surgery?

No. A rising CA-125 alone does not determine whether surgery is needed. Doctors interpret the trend with symptoms, examination, imaging, previous treatment and the overall disease pattern.

Is secondary CRS the same as the first ovarian cancer operation?

Both aim to remove visible disease, but secondary CRS is performed after cancer has returned. Previous surgery, scar tissue and the new pattern of disease can make the planning and procedures different.

Will the spleen always be removed during secondary CRS?

No. Splenectomy is considered only when disease involving the spleen or nearby structures makes removal necessary for the surgical goal. Most patients being assessed for recurrent ovarian cancer do not automatically need their spleen removed.

Can surgery cure recurrent ovarian cancer?

Surgery should not be presented as a guaranteed cure. In carefully selected patients, complete secondary CRS may improve disease control and may improve survival, but recurrence can still occur and additional treatment is often required.

Medical references

This information is for general education. It cannot determine whether secondary CRS, splenectomy, chemotherapy or another treatment is appropriate for an individual patient.

Book a consultation to review recurrence scans, previous treatment and whether a surgical assessment is appropriate.